Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2018 Photo Eugene Seegers
Theological faculty highlights reconciliation as Biblical imperative
Prof Bram van de Beek (Liturgist; Emeritus Professor, VU Amsterdam); Prof Fanie Snyman (Dean: Faculty of Theology and Religion, UFS); Prof Nelus Niemandt (Guest speaker; Department: Science of Religion and Missiology, University of Pretoria); and Prof Mary-Anne Plaatjies-Van Huffel (Guest speaker; Department of Systematic Theology and Ecclesiology, University of Stellenbosch) at the UFS theological faculty’s official opening in Bloemfontein.

Does the current South African context and reality still allow for discussions around the topic of forgiveness and reconciliation? This was one of the themes discussed at the annual opening and Theological Day of the Faculty of Theology and Religion at the University of the Free State (UFS), which experienced a record attendance figure this year.

After welcoming staff members from the broader university community and from within the faculty, as well as guest speakers and international visitors such as Prof Bram van de Beek from the Free University Amsterdam (the Netherlands) and Dr Stefan Fischer from the University of Vienna (Austria), Prof Fanie Snyman, Dean of the faculty, stated, “We want to welcome pastors, dominees, reverends, fathers, spiritual leaders from a variety of church denominations.” He added, “I would also like to extend a special word of welcome to alumni of this faculty, who have kept their interest in our faculty alive by being present here.”

Reconciliation: Biblical imperative
In his sermon, Prof Bram van de Beek (VU Amsterdam) pointed out that “reconciliation is the Christian way, the way of love; therefore, to serve others should be more important to us than serving ourselves.” He explained further that, as humans, we run the risk of merely thinking about what is best for us, but to be true followers of Christ, we need to let others take priority.

Prof Mary-Anne Plaatjies-Van Huffel from the Department of Systematic Theology and Ecclesiology at the University of Stellenbosch’s Faculty of Theology spoke on Moving from forgiveness to reconciliation—Reconciliation as a fundamental Biblical category. She expanded on the Old Testament understanding of reconciliation as a means of repentance, atonement, and — ultimately — forgiveness.

The Jewish festivals of Rosh Hashanah and Yom Kippur, as well as the Biblical events recorded between Jacob and Esau in Genesis Chapter 33 were cited as examples of this understanding. Prof Plaatjies-Van Huffel said, “Having to face a painful past is a prerequisite for reconciliation,” adding that “broken relationships are only restored by the grace of God, who is the Author of reconciliation.” However, the responsibility for carrying out this message to the world belongs to each Christian, who must individually actuate divine reconciliation by the example they set, she concluded.

The reality of the post-Zuma South African landscape
Prof Nelus Niemandt, from the Department of Science of Religion and Missiology at the University of Pretoria, presented a paper entitled Competing narraphors in the post-Zuma landscape. His presentation painted a vivid narrative of the enormously complex time of rapid, radical change with which we as humans are ill-equipped to cope or to which we cannot adapt quickly enough. He highlighted several examples of the paradoxes evident in the world today, such as our mobile worldwide society versus the mass displacement of humans which creates migrants and strangers across the globe, or a growing super-diversity that feeds increased nationalism, racism, or fundamentalism, all of which challenge any preconceptions we may have of reconciliation.

He concluded with this expression: “My hope is that the Faculty of Theology and Religion at the UFS will be such eloquent storytellers that they will shape the imagination with narraphors of Christ’s future Kingdom.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept